What are the side effects of Vepotolizumab/Urova?

As an antibody-conjugated drug, Polatuzumab/Polatuzumab has shown a certain spectrum of side effects in clinical applications (non-Hodgkin lymphoma), including both drug-specific target-related toxicity and synergistic adverse reactions when combined with chemotherapy. The main side effects involve the blood system, liver function, nervous system and infection risk. Hematologic toxicities were the most common and included neutropenia, thrombocytopenia, and anemia. These adverse reactions are particularly prominent in combination chemotherapy regimens, so blood levels need to be monitored regularly during treatment, and drug dosages should be adjusted or delayed if necessary to prevent serious infections or bleeding events.

Nervous system toxicity mainly manifests as peripheral neuropathy, including numbness, tingling, or decreased muscle strength in the hands and feet. This is related to drug-conjugated cytotoxic MMAE, which inhibits tumor cell division through microtubule interference, but may also produce mild toxicity in some nerve endings. Patients should pay attention to self-observation of changes in neurological function during medication. If persistent numbness or abnormal gait occurs, they should promptly inform the doctor. Abnormal liver function is also one of the common clinical side effects, manifested as elevated transaminases or elevated bilirubin. Therefore, liver function indicators need to be monitored regularly before and during treatment to avoid drug-induced liver injury.

Additionally, the increased risk of infection is another important aspect to focus on. Because drugs may cause immunosuppression, especially when neutropenic, patients are more susceptible to bacterial or viral infections. Therefore, it is recommended to strictly implement infection prevention measures during treatment and seek medical attention immediately if fever, cough or other infection symptoms occur. Some patients may also experience gastrointestinal reactions such as nausea, vomiting, diarrhea, or loss of appetite. Although most side effects can be controlled through supportive therapy or dose adjustment, individual differences are significant, and some patients may experience serious adverse reactions that require immediate discontinuation of medication and symptomatic treatment.

Reference materials:https://www.drugs.com/polivy.html